FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a B-cell maturation antigen (BCMA)-binding molecule that specifically binds to human BCMA, a conjugate for treating a subject with a disease or disorder associated with the expression of BCMA, a pharmaceutical composition for treating a subject with a disease or disorder associated with the expression BCMA, a method of treating a subject with a disease or disorder associated with BCMA expression, use of a BCMA binding molecule, conjugate or pharmaceutical composition in the manufacture of a medicinal product for treating a disease or disorder associated with BCMA expression, use of a BCMA binding molecule, conjugate or pharmaceutical composition for treating a disease or disorder associated with the expression of BCMA, a nucleic acid encoding a BCMA-binding molecule, a cell engineered to express the BCMA-binding molecule, a cell for producing the BCMA-binding molecule, and a method of producing the BCMA-binding molecule.
EFFECT: invention expands the arsenal of agents that specifically bind to B-cell maturation antigen (BCMA).
50 cl, 139 dwg, 75 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
| METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
